A new FLOW analysis reports that semaglutide kidney and all-cause death benefits were consistent across cardiovascular-risk groups in adults with type 2 diabetes and chronic kidney disease.
New Research Confirms GLP-1 Medications Protect the Heart, Not Just Blood Sugar: cardiovascular outcome trial evidence, who benefits most, and how this drug.
